Nuwellis, Inc. (NUWE)

Nuwellis, Inc.'s stock price has experienced a significant decline over the past year. Key events impacting the stock in the past six months include the acquisition of Rendiatech in March 2026 to expand its technology portfolio. The company announced its Q4 and full-year 2025 financial results in March 2026, reporting a 4% year-over-year revenue increase for Q4 2025. Nuwellis reported that its pediatric segment achieved approximately 50% of its total U.S. revenue in 2025. In April 2026, Nuwellis strengthened its commercial infrastructure by creating a new South Texas territory. In March 2026, two board members resigned, citing disagreements over the timeliness of information provided by the company. In April 2026, Nuwellis retained CORE IR for investor relations, public relations, and social media management services. The company has undergone several reverse stock splits in recent years.

While there is no explicit information detailing strong seasonality for Nuwellis, Inc.'s specific ultrafiltration products for fluid overload, general trends in the medical device market can offer some insight. The broader market for fluid management systems is primarily driven by the increasing prevalence of chronic conditions and a growing number of surgical procedures, suggesting a more consistent demand for Nuwellis's products rather than significant seasonal fluctuations.

Nuwellis, Inc. is a medical technology company focused on developing and commercializing medical devices for ultrafiltration therapy, primarily addressing fluid overload in patients with complex cardio-renal conditions. The company operates within the Healthcare sector and the Medical Devices industry, focusing on precision fluid management. Its major products include the Aquadex FlexFlow and Aquadex SmartFlow systems, used to treat patients experiencing fluid overload, particularly those with heart failure. Nuwellis is also developing the Vivian pediatric CRRT system and aims to advance precision fluid management therapies to improve outcomes for patients with cardiorenal conditions, including expanding into hospital-based outpatient therapy and supporting pediatric innovation.

Nuwellis, Inc. is headquartered in Eden Prairie, Minnesota, and maintains a wholly-owned subsidiary in Ireland. The company sells its products through a direct salesforce in the United States and distributes internationally through specialty healthcare distributors in various countries. Recently, Nuwellis announced the creation of a dedicated South Texas commercial territory to strengthen its presence in key U.S. hospital markets.

Nuwellis's brand reputation has been influenced by strategic advancements and governance challenges. The company's focus on expanding its pediatric footprint and the acquisition of Rendiatech contribute positively to its reputation. However, the resignations of two board members in March 2026 could have negatively impacted its reputation regarding corporate governance and transparency. The company's decision to engage CORE IR suggests a proactive effort to manage its public image and enhance communication with shareholders.

The ownership structure of Nuwellis (NUWE) stock is a mix of institutional, insider, and retail investors. Approximately 4.65% to 6.97% of the company's stock is held by institutional investors, while insiders own a significant portion, around 47.61% to 75.82%. Retail investors hold approximately 47.70% of the stock. Major institutional owners include Sabby Management, Llc, DRW Securities, LLC, and Geode Capital Management, Llc. John Erb, the CEO and President, is noted as owning a significant number of shares.